Alpback Workshop

MENU menu

10th Alpbach Workshop on
Affinity Proteomics
10th to 13th March 2024



Cambridge Protein Arrays Ltd are the European distributors and service providers for HuProt™ human proteome arrays, the largest human protein arrays available, with more than 21,000 human proteins, representing more than 16,000 human genes on a single microscope slide. HuProt™ arrays are designed for screening of antibody specificity, autoantibody profiling, and protein-protein or protein-ligand interactions. CPA is a biotech SME founded in 2010 by Mike Taussig, located in Cambridge, UK. With strong roots in the European Affinity Proteomics community, we are also the organisers of the Alpbach Workshops in Affinity Proteomics.


Explore our extensive portfolio of more than 74,000 high-quality primary and secondary antibodies ( covering over 85% of the proteome, supported by an extensive range of antibody-related products and custom services. Our antibody assays are validated by thousands of citations worldwide, helping you achieve superior results in a wide range of detection and purification applications.



GeneTex is a multinational antibody manufacturer with 25 years of experience producing immunological reagents for biomedical research. The company maintains an extensive portfolio of primary antibodies in polyclonal and hybridoma-based monoclonal formats, but as of 2020 transitioned entirely to recombinant monoclonal antibody production. This platform involves multi-parameter FACS-based isolation of antigen-specific IgG memory B cells from an immunized animal (primarily rabbits) with subsequent antibody heavy and light chain cloning and expression in mammalian cells. In conjunction with its recombinant antibody platform, GeneTex expanded its reagent validation protocols to more closely align with the “Five Pillars” paradigm described by Uhlen et al. (2016). Particular emphasis is placed on employing shRNA knockdown (KD) or CRISPR-mediated knockout (KO) approaches. GeneTex is dedicated to producing immunological reagents through extensive product development programs, collaborations with leading researchers, and stringent validation strategies.


CDI Laboratories products and services are based on our suite of high-content protein library platforms.

  • HuProtTM protein array: The world’s largest human protein array with 82% coverage of the human proteome (>21,000 full-length proteins)
  • PhIP-seq (phage display, immunoprecipitation, sequencing). 
    (HuScanTM) human proteome library; (MouseScanTM) mouse proteome library

CDI utilizes these platforms to provide services for immune biomarker discovery in oncology and autoimmune disease, predictive diagnostic assay development, autoimmune profiling, and protein interactome assays.


At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.


In addition to being a well-known market leader in life science supply and diagnostics, Bio-Rad is very active in developing and manufacturing high-quality, bespoke antibodies for Life Science and Biopharma customers. Our Custom Antibody Service has developed more than 60,000 antibodies and now also offers biotherapeutic antibody discovery. The Pioneer™ Antibody Discovery Platform uses a phage display library of >200 billion unique functional antibodies, unprecedented diversity in LCDR3 and HCDR3, and animal-free screening for accelerated candidate selection. The Pioneer Platform enables our partners to rapidly expand their biologics pipelines with high-performance leads. 


At Abbratech our focus is on ‘precision antibodies’. We want to be able to derive antibodies to specific sites on an antigen at a nearly amino acid resolution. Regardless of target immunogenicity, tolerance, or modification. No longer should a discovery antibody be about ‘what is a good epitope?’ It now becomes ‘where do you want the antibody to bind?'


YUMAB develops therapeutic antibodies from its proprietary universal human antibody libraries (>10e11), patient derived libraries and immune libraries (llama, rabbit, chicken, mouse, rat, dog, cat, transgenic animals …). YUMAB’s integrated antibody platform offers fast-track antibody discovery with high success-rates also for “difficult” targets delivering antibody candidates suitable for all modalities and indications. Its advanced antibody engineering technologies using a combination of bioinformatics and experimental approaches resulting in optimized lead sequences. YUMAB has a strong track record more than 250 R&D projects from startup to big pharma in 10 years and is also active in a number of collaborations, funded R&D projects, and new startups including the spin-out CORAT Therapeutics, which needed only 11 months from target to the clinics for its COR-101 antibody program.


Atlas Antibodies is a Swedish biotech company manufacturing and distributing over 22,000 primary antibodies for tissue and cell analysis to explore and accelerate research in biology, pathology, and medicine. Atlas Antibodies stems from the Human Protein Atlas project. Our portfolio include Triple A PolyclonalsTM (the antibodies from the Human Protein Atlas), PrecisA MonoclonalsTM and PrEST AntigensTM covering different research areas such as neuroscience, cancer, cell biology, stem cell and development. All our products are rigorously evaluated for specificity, reproducibility and performance and characterized for use in IHC, WB, and ICC-IF. Application-specific enhanced validation is applied as an extra level of security of antibody specificity in a defined context. Made by researchers for researchers our products are used all over the world and referenced in thousands of scientific peer reviewed papers. Our company is built on a solid foundation where innovative and creative mindsets are combined with the latest techniques and technologies. Our culture empowers individuals to work as a team, and our coworkers are responsible and passionate. To know more, visit us at:


The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 3,000 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,200 scientists investigate how cancer develops, identify cancer risk factors and work at new strategies to prevent people from getting cancer. They develop novel approaches to make tumour diagnosis more precise and treatment of cancer patients more successful.



Maxion has developed an innovative KnotBody® technology that combines the power of millions of years of knottin (naturally occurring miniproteins) evolution in modulating ion channels and GPCRs with state-Of-the-art antibody engineering techniques. On their own, knottins are excellent modulators of ion channels but have poor drug-like properties. However, once they are fused onto the surface of antibodies, the resulting “KnotBodies” offer a powerful combination of the functional activity of knottins and the desirable drug properties of antibodies. This revolutionary technology addresses targets that have been off-limits to both small molecules and traditional antibody approaches and results in first-in-class and best-in-class drug candidates.  Founded in 2020 and based in Cambridge (UK), Maxion Therapeutics is driven by an experienced team with an excellent track record. CEO and co-founder Dr John McCafferty (previously co-founder of Cambridge Antibody Technology and IONTAS) and CSO and co-founder Dr Aneesh Karatt-Vellatt (co-founder of IONTAS) co-invented KnotBody technology.





Elsevier is a world-leading provider of information solutions that enhance the performance of science, health and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. We provide web-based, digital solutions — among them ScienceDirect, Scopus, Evolve, Knovel, Reaxys and ClinicalKey — and publish over 2,500 journals and more than 33,000 book titles. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.